title: [Effects of fluoxetine and its complexes with glycyrrizhinic acid on behavior and brain monoamine levels in rats].
abstract: Effects of serotonin uptake inhibitor fluoxetine (F) and it's complexes with glycyrrizhinic acid (GA) in molar proportions 1GA : 1F (FGA-1) and 4GA : 1F (FGA-4) on rat behavior in elevated plus-maze and brain monoamine concentrations were studied. Drugs (25 mg/kg) were administered per os 1 h before investigations. F-treated rats showed increased anxiety and reduced locomotor activity, whereas FGA-1 and FGA-4 had no effects on the behaviors. None of the compounds modified brain tissue serotonin content, but all of them decreased the level of its metabolite 5-hydroxyindole-3-acetic acid level in the hypothalamus, and FGA-4 also decreased it in the cortex. Noradrenaline levels were increased in the hypothalamus of rats treated with F in both combinations with GA. In the striatum, F increased dopamine and its metabolite DOPAC levels, but their ratio (an indicator of the neurotransmitter turnover) was not altered by this drug. Unlike F, FGA-1 significantly activated dopamine turnover in the striatum. The data obtained suggested that application of F in complexes with GA significantly modified the drug behavioral effects and these alterations may be related to specific effects of the pure compound and its complexes on the functions of the brain monoaminergic systems that regulate investigated behavior.
authors.forename: G T
authors.initials: GT
authors.lastname: Shishkina
authors.forename: N N
authors.initials: NN
authors.lastname: Dygalo
authors.forename: A M
authors.initials: AM
authors.lastname: Iudina
authors.forename: T S
authors.initials: TS
authors.lastname: Kalinina
authors.forename: T G
authors.initials: TG
authors.lastname: Tolstikova
authors.forename: I V
authors.initials: IV
authors.lastname: Sorokina
authors.forename: I L
authors.initials: IL
authors.lastname: Kovalenko
authors.forename: L V
authors.initials: LV
authors.lastname: Anikina
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects*; D015306:Biogenic Monoamines / Q000378:metabolism*; D001921:Brain / Q000187:drug effects*; D004298:Dopamine / Q000378:metabolism; D005473:Fluoxetine / Q000008:administration & dosage / Q000494:pharmacology*; D019695:Glycyrrhizic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D008124:Locomotion / Q000187:drug effects; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012701:Serotonin / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000890:Anti-Infective Agents; D015306:Biogenic Monoamines; D004298:Dopamine; D005473:Fluoxetine; D019695:Glycyrrhizic Acid; D006897:Hydroxyindoleacetic Acid; D009638:Norepinephrine; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors